Wells Fargo Downgrades Rigel Pharmaceuticals (RIGL) to Market Perform Following OSKIRA Study
Tweet Send to a Friend
Wells Fargo downgraded Rigel Pharmaceuticals (NASDAQ: RIGL) from Outperform to Market Perform with a price target of $5 to $7 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
